Achilles Therapeutics plc 698.MU Stock
Achilles Therapeutics plc Price Chart
Achilles Therapeutics plc 698.MU Financial and Trading Overview
| Achilles Therapeutics plc stock price | 0.78 EUR |
| Previous Close | 0.9 EUR |
| Open | 0.9 EUR |
| Bid | 0.9 EUR x N/A |
| Ask | 0.93 EUR x N/A |
| Day's Range | 0.9 - 0.9 EUR |
| 52 Week Range | 0.75 - 3.28 EUR |
| Volume | 7.01K EUR |
| Avg. Volume | 222 EUR |
| Market Cap | 37.19M EUR |
| Beta (5Y Monthly) | 0.927152 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.62 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
698.MU Valuation Measures
| Enterprise Value | -116880088 EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.19898298 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 1.744 |
Trading Information
Achilles Therapeutics plc Stock Price History
| Beta (5Y Monthly) | 0.927152 |
| 52-Week Change | -58.71% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.28 EUR |
| 52 Week Low | 0.75 EUR |
| 50-Day Moving Average | 0.86 EUR |
| 200-Day Moving Average | 1.44 EUR |
698.MU Share Statistics
| Avg. Volume (3 month) | 222 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 40.94M |
| Float | 17.9M |
| Short Ratio | N/A |
| % Held by Insiders | 5.96% |
| % Held by Institutions | 61.38% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -17.69% |
| Return on Equity (ttm) | -31.58% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -67022000 EUR |
| Net Income Avi to Common (ttm) | -71327000 EUR |
| Diluted EPS (ttm) | -1.62 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 158.46M EUR |
| Total Cash Per Share (mrq) | 3.87 EUR |
| Total Debt (mrq) | 7.6M EUR |
| Total Debt/Equity (mrq) | 4.11 EUR |
| Current Ratio (mrq) | 10.323 |
| Book Value Per Share (mrq) | 4.523 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -56753000 EUR |
| Levered Free Cash Flow (ttm) | -43830376 EUR |
Profile of Achilles Therapeutics plc
| Country | Germany |
| State | N/A |
| City | London |
| Address | 245 Hammersmith Road |
| ZIP | W6 8PW |
| Phone | 44 20 8154 4600 |
| Website | https://www.achillestx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 234 |
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Q&A For Achilles Therapeutics plc Stock
What is a current 698.MU stock price?
Achilles Therapeutics plc 698.MU stock price today per share is 0.78 EUR.
How to purchase Achilles Therapeutics plc stock?
You can buy 698.MU shares on the Munich exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Achilles Therapeutics plc?
The stock symbol or ticker of Achilles Therapeutics plc is 698.MU.
Which industry does the Achilles Therapeutics plc company belong to?
The Achilles Therapeutics plc industry is Biotechnology.
How many shares does Achilles Therapeutics plc have in circulation?
The max supply of Achilles Therapeutics plc shares is 42.16M.
What is Achilles Therapeutics plc Price to Earnings Ratio (PE Ratio)?
Achilles Therapeutics plc PE Ratio is now.
What was Achilles Therapeutics plc earnings per share over the trailing 12 months (TTM)?
Achilles Therapeutics plc EPS is -1.62 EUR over the trailing 12 months.
Which sector does the Achilles Therapeutics plc company belong to?
The Achilles Therapeutics plc sector is Healthcare.